Wrap up: Clevor receives expiration date extension from FDA, and other news

tumskaia/stock.adobe.com

Happy Friday dvm360 readers! We hope everyone had an amazing week and are ready for a much-earned weekend. With the countdown to Fetch Kansas City continuing to dwindle down, registration remains open! You can register here today to secure a spot among our amazing attendees and fantastic faculty for a weekend full of learning and fun. Learn from experts on topics ranging from large animal medicine to hospital design, and more!

As you register for Kansas City, here are this week’s article highlights:

• The FDA declared earlier this week that it has approved a 3-year expiration date expansion for Vetoquinol’s Clevor, a ropinirole ophthalmic solution, when it is stored within its original package.
• Our latest installment of the Clinic center featuring veterinary and pet facilities opening across the United States is now available! This recent version including a veterinary dental clinic in New Jersey, a new CityVet location in Oklahoma, and the nation’s first dog hygiene and wellness franchise in South Carolina.
• On this week’s episode of The Vet Blast Podcast, Baran Schultz, owner of Schutlz Technology, shared some insights and innovations of technological advances in veterinary medicine and how they are keeping staff, patients, and clients safe and healthy.
• Vicki J. Pollard, AIA, NCARB, CVT, AAA, an architect from Animal Arts, discussed in a recent article the essential components and design considerations for a well-functioning pack prep area in veterinary hospitals.
• During an interview with Jill Clark, DVM, Clark shares the differences between empathy and sympathy to help attendees in her lecture understand the place each of these feelings has in the clinic, and how it can help them connect with clients.
• Dechra Limited announced that it purchased Akston Biosciences Corporation’s long-acting veterinary insulin program, giving the company ownership of the intellectual property and rights for the development, manufacturing, and worldwide commercialization of the canine and feline candidate therapies
• And more!